Lee’s Pharmaceutical Holdings Ltd (HKG: 0950), a China-based pharmaceutical company, through its subsidiary Zhaoke Ophthalmology Ltd (HKG: 6622), has announced a distribution and supply agreement with South Korea’s Kwangdong Pharmaceutical Co., Ltd. The agreement pertains to Brimochol PF, a preservative-free fixed dose of carbachol and bromonidine tartrate, which serves as a choline preparation and an α compound formula of a 2-receptor agonist.
Under the terms of the deal, Kwangdong Pharmaceutical will have the exclusive rights to import, promote, distribute, and market the drug in South Korea. Zhaoke Ophthalmology will receive an undisclosed upfront payment and is eligible for milestone payments and royalties.
Brimochol PF is indicated for the correction of loss of close range vision due to presbyopia. It has been demonstrated to significantly improve patients’ 8-hour close range vision and is well-tolerated, as shown in the Phase III BRIO-I study. The drug works by causing pupil constriction, creating a pinhole effect that allows only centrally focused light to enter the eye. This effect enhances the sharpness and clarity of short to medium distance images, which is beneficial for activities such as reading, using smartphones, and browsing computer monitors.- Flcube.com
